Replies to post #701950 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

>>>At some point it has to stop being an endless science experiment and become a profitable business.<<<

This is a critical observation that a few here should note. This leased out 1st iteration of UCLA's proprietary biotech, has remained stagnate under NWBO's watch, with all improvements carried out by Dr Liau alone.

And her recent adaptation works, indicates that DCVAX-L was far from a viable finished product, and a clear indication that she has processionally & academically stepped away from Northwest BioTherapeutics. With this Biotech lately just getting a footnoted trial reference.

So to investors here, care less about the scientific future research of dendritic cell use, and just look at what you have your money invested in NOW with NWBO

[theorysuit]

Have you looked around. It has been profitable for LP and her friends. It just hasn't been profitable for shareholders. You think building out cognate and now advent is profitable for shareholders? So advent directly collects the revenue and the split between advent and nwbo is still unknown. That sounds fantastic for the owner of advent cough cough LP. But hell that information is just FUD the pumpers will say.

https://find-and-update.company-information.service.gov.uk/company/08717711/persons-with-significant-control

[Doc logic]

vator,

Do you really think that big pharma wanted to help NWBO with manufacturing and supply chain issues to the detriment of their PRIMARY position with checkpoint inhibitors which their own research back in 2013/2014 demonstrated would be reduced to secondary or lower by DC therapy?; ). Do you think they wanted Direct trials to be funded from a partnership while L was finishing up with this proof when Direct was working solo?; ). They didn’t want NWBO to be a profitable business and investors have paid the price for that.
Sure, management could have sold more shares at higher prices to create less dilution but even they did not know that they did not know how long this all would take so they chose slow and steady which often led to financing near the lower end of interim pricing. In the interim this gave them opportunity to maintain more control of the company with options and stock awards and allowed other strong longs to reduce their cost basis during the wait which is the opposite of what manipulators wanted but ended up with.
Getting diluted from a higher percentage of the company to a lower one stinks but that can also be considered part of the damages a jury might be asked to consider when placed in a correct model of loss causation. Bottom line is that most people still do not know the NWBO story and when they do, the outrage against the perps will manifest proportionally to the number of families impacted by cancer who finally understand what they have done. If you want to see a profitable business then watch what happens when this story finally reaches the masses; ). Best wishes.